Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

Minimal nAb titers against Omicron in the elderly after 3rd dose

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Omicron surges in England especially in young

Omicron surges in England especially in young

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Echinacea, a potent antiviral against SARS-CoV-2

Echinacea, a potent antiviral against SARS-CoV-2

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Altered cytokine profiles of COVID-19-infected mother-infant dyads may impair long-term infant health

Altered cytokine profiles of COVID-19-infected mother-infant dyads may impair long-term infant health

Omicron infection induces cross-reactive immune responses

Omicron infection induces cross-reactive immune responses

COVID-19 vaccine appears safe in children aged 5–11 Years

COVID-19 vaccine appears safe in children aged 5–11 Years

SARS-CoV-2 omicron variant may be less severe than the delta variant

SARS-CoV-2 omicron variant may be less severe than the delta variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A reliable assessment of COVID-19 vaccine protection duration

A reliable assessment of COVID-19 vaccine protection duration

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.